Managing Risk Under the Physician Payment Sunshine Law and Anti-kickback Statute

is being presented by Sheva Sanders, Partner with, Leonard, Street and Deinard and airs on Wednesday, June 29th, 2011. For more details, or to register please visit our site at www.fxconferences.com

As device-related therapies have become more complex, and technological capabilities have become more sophisticated, medical device companies have expanded their activities in support of those therapies. For example, many companies provide substantial and valuable support related to stocking their products, training and education on the use of their products, reimbursement-related support, and post-implant monitoring.

At the same time, laws such as the Physician Sunshine Payment Act and the Anti-kickback Statute – focusing on the perceived conflict of interest created through the transfer of value to provider-customers – have made it critical to be able to identify reportable or prohibited transfers of value.

This audio conference presentation explores the question of whether and when the product-related support activities are reportable under the Physician Sunshine Payment Act and similar state statutes, and whether and when such activities might constitute remuneration under the federal Anti-kickback Statute and similar state statutes.

Industry Update: Federal and State Aggregate Spend Requirements

is being presented by John Patrick Oroho, Principal, Porzio, Bromberg & Newman, P.C. and airs on Wednesday, April 6th, 2011. For more details or to register, please visit our site at www.fxconferences.com

The Physician Payment Sunshine Act became law as part of healthcare reform measures in 2010. Life science companies are now required to track, aggregate and disclose the amount they append on physician payments and transfers of value and gifts (i.e. meals, etc.). Federal regulations for the Sunshine Act are to be promulgated by October 2011. However, since spend transactions need to be captured for federal reporting purposes beginning on January 1, 2012, it is necessary to start to preparing before the regulations are published.

At the same time, several state legislatures are also establishing and passing their own laws which influence how life science companies can carry out business in those locales.

In this audio conference presentation we look at what type of information will need to be captured and reported pursuant to the Sunshine Act. The speaker also provides an update on state activities, with information relating to drug samples, laws governing lobbying, and other local regulations of particular concern to life science companies.